Table 1 Published clinical trials of TCR-T treatment for solid tumors
From: Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Year | Target | Type of antigen | HLA Allele | Tumor Type | NO. Patients | Efficacy (ORR, %) | Adverse Effects (%) | Clinical Trial Phase | Ref. |
|---|---|---|---|---|---|---|---|---|---|
2022 | KRASG12D | TSA | C*08:01 | pancreatic carcinoma | 2 | 50.0% | none (grade 3–5) | I | [49] |
2021 | E7 | TSA | A*02:01 | HPV-associated | 12 | 50.0% | none (grade 3–5) | I | [72] |
2021 | MAGE-A4 | CGA | A*02 | synovial sarcoma, | 37 | 39.0% | CRS (59.5%) | II | [63]a |
2020 | MAGE-A4 | CGA | A*02 | various solid tumors | 5 | 40.0% | none (grade 3–5) | I | [63]a |
2020 | MAGE-A4 | CGA | A*02 | various solid tumors | 34 | 25.0% | 2 death (5.9%) | I | [63]a |
2019 | E6 | TSA | A*02:01 | HPV-associated solid | 12 | 16.7% | none (grade 3–5) | I/II | [106] |
2019 | NY-ESO-1 | CGA | A*02 | synovial sarcoma | 42 | 35.7% | CRS (11,9%) | I/II | [107] |
2019 | NY-ESO-1 | CGA | A*02:01 | various solid tumors | 9 | 33.3% | none | I | [63]a |
2019 | NY-ESO-1 | CGA | A*02:01 | various solid tumors | 9 | 22.2% | CRS (55.6%) | Ib | [63]a |
2019 | NY-ESO-1 | CGA | A*02:01 | various solid tumors | 10 | 20.0% | none (grade 3–5) | I | [78] |
2018 | Tyrosinase | TAA | A*02 | melanoma | 3 | 33.0% | vitiligo (66.7%) | I | [108] |
2018 | MAGE-A10 | CGA | A*02 | various solid tumors | 8 | 0.0% | CRS (25%) | I | [63]a |
2017 | MAGE-A3 | CGA | DPB1*04:01 | various solid tumors | 17 | 23.5% | fever (58.8%), liver or renal dysfunction (11.8%) | I/II | [77] |
2016 | KRASG12D | TSA | C*08:01 | colorectal carcinoma | 1 | partial remission | none (grade 3–5) | I | [48] |
2015 | NY-ESO-1 | CGA | A*02:01 | melanoma; synovial sarcoma | 38 | 58.0% | none (grade 3–5) | II | [105] |
2015 | MAGE-A4 | CGA | A*24:02 | esophageal cancer | 10 | 0.0% | none (grade 3–5) | I | [80] |
2014 | MART-1 | TAA | A*02:01 | melanoma | 14 | 0.0% | erythematous skin rash (21.4%), acute respiratory distress syndrome (14.3%) | II | [109] |
2013 | MAGE-A3 | CGA | A*02:01 | various solid tumors | 9 | 55.6% | neurological toxicity (33.3%) | I/II | [76] |
2011 | CEA | TAA | A*02:01 | colorectal cancer | 3 | 33.3% | severe colitis (100%) | I/II | [110] |
2009 | MART-1 | TAA | A*02:01 | melanoma | 20 | 30.0% | skin toxicity (70%), uveitis (60%), hearing loss (50%) | II | [111] |
2009 | gp100 | TAA | A*02:01 | melanoma | 16 | 18.8% | skin toxicity (93.8%), hearing loss (31.3%, uveitis (25%), | I/II | [111] |
2006 | MART-1 | TAA | A*02:01 | melanoma | 17 | 12.0% | none | I/II | [112] |